de Vos, Filip - Resultats de la cerca - Dipòsit Digital de Documents de la UAB

Cerca col·leccions:

Ordena'ls per:	Mostrar els resultats:	Format de visualizació:

Resultats globals: 2 registres trobats en 0.03 segons.
Articles, 2 registres trobats

Articles	2 registres trobats

12 p, 506.4 KB

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia / Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ; DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ; Chromik, Jörg (Goethe University Frankfurt) ; Chatterjee, Manik (University Hospital of Würzburg) ; Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ; de Vos, Filip (University Medical Center Utrecht) ; Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Cassier, Philippe A. (Léon Bérard Center) ; Tai, David (National Cancer Center Singapore) ; Kiladjian, Jean-Jacques (Université de Paris) ; Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ; Mous, Rogier (University Medical Center Utrecht) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ; Ferretti, Stephane (Novartis Institutes for Biomedical Research) ; Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ; Meille, Christophe (Novartis Institutes for Biomedical Research) ; Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ; Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ; Mariconti, Luisa (Novartis Institutes for Biomedical Research) ; Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ; Fabre, Claire (Novartis Institutes for Biomedical Research) ; Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 - DOI (Digital Object Identifier)

10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881

Registre complet -

11 p, 632.8 KB

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma / Vieito, María (Vall d'Hebron Institut d'Oncologia) ; Simonelli, Matteo (Humanitas Research Hospital (Itàlia)) ; de Vos, Filip (University Medical Center Utrecht) ; Geurts, Marjolein (Erasmus MC Cancer Institute (Holanda)) ; Lorenzi, Elena (Humanitas Research Hospital (Itàlia)) ; Macchini, Marina (San Raffaele Scientific Institute (Itàlia)) ; van den Bent, Martin J (Erasmus MC Cancer Institute (Holanda)) ; Del Conte, Gianluca (San Raffaele Scientific Institute (Itàlia)) ; de Jonge, Maja (Erasmus MC Cancer Institute (Holanda)) ; Martín-Soberón, Maria Cruz (Hospital Universitario 12 de Octubre (Madrid)) ; Amoroso, Barbara (A Bristol Myers Squibb Company (Sevilla)) ; Sanchez-Perez, Tania (Bristol Myers Squibb Company (Sevilla)) ; Zuraek, Marlene (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Hanna, Bishoy (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Aronchik, Ida (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Filvaroff, Ellen (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Chang, Henry (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Mendez, Cristina (Bristol Myers Squibb (Sevilla)) ; Arias Parro, Marina (Bristol Myers Squibb (Suïssa)) ; Wei, Xin (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Nikolova, Zariana (Bristol Myers Squibb (Sevilla)) ; Sepulveda, Juan Manuel (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
Standard-of-care treatment for newly diagnosed glioblastoma (ndGBM), consisting of surgery followed by radiotherapy (RT) and temozolomide (TMZ), has improved outcomes compared with RT alone; however, prognosis remains poor. [...]
2022 - DOI (Digital Object Identifier)

10.1093/noajnl/vdac146
Neuro-oncology Advances, Vol. 4 (october 2022)

Registre complet -

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.